Results 21 to 30 of about 6,741,320 (294)

Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension [PDF]

, 2011
Background: Endothelin-1 signalling plays an important role in pathogenesis of pulmonary hypertension. Although different endothelin-A receptor antagonists are developed, a novel therapeutic option to cure the disease is still needed.
Norbert Weissmann, Sydykov, Akylbek, Brandes, Ralf, Schermuly, Ralph T., Hossein A Ghofrani, Janssen, Wiebke, Seeger Werner, Ralf P Brandes, Neil Davie, Dahal, Bhola K., Davie, Neil, Janssen Wiebke, Davie Neil, Ghofrani Hossein A, Seeger, Werner, Cornitescu, Teodora, Brandes Ralf P, Cornitescu Teodora, Kosanovic, Djuro, Kojonazarov, Baktybek, Werner Seeger, Friedrich Grimminger, Ghofrani, Hossein Ardeschir, Grimminger, Friedrich, Dahal Bhola K, Djuro Kosanovic, Baktybek Kojonazarov, Teodora Cornitescu, Schermuly Ralph T, Sydykov Akylbek, Wiebke Janssen, Grimminger Friedrich, Akylbek Sydykov, Kojonazarov Baktybek, Weissmann Norbert, Himal Luitel, Luitel Himal, Ralph T Schermuly, Luitel, Himal, Weißmann, Norbert, Bhola K Dahal, Kosanovic Djuro   +41 more
core   +2 more sources

Cardiovascular pathology in patients with newly diagnosed tuberculosis and chronic obstructive pulmonary disease

Медицинский совет, 2021
Introduction. Chronic obstructive pulmonary disease and cardiovascular diseases (arterial hypertension, ischemic heart disease, chronic heart failure) are among the comorbid conditions that mutually aggravate each other.
N. V. Bagisheva, A. V. Mordyk, I. A. Viktorova, D. I. Trukhan   +3 more
doaj   +1 more source

THE HEART IN PULMONARY TUBERCULOSIS [PDF]

Southern Medical Journal, 1908
n ...
openaire   +1 more source

Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease

Pulmonary Circulation, 2018
There are few randomised controlled data to guide management of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD).
R. Condliffe, P. Clift, K. Dimopoulos, R.M.R. Tulloh   +3 more
doaj   +1 more source

Stem cell therapy in pulmonary hypertension: current practice and future opportunities

European Respiratory Review, 2023
Pulmonary hypertension (PH) is a progressive disease characterised by elevated pulmonary arterial pressure and right-sided heart failure. While conventional drug therapies, including prostacyclin analogues, endothelin receptor antagonists and ...
Ruixuan Zheng, Tingting Xu, Xinghong Wang, Lehe Yang, Jian Wang, Xiaoying Huang   +5 more
doaj   +1 more source

Transforming growth factor-beta receptor mutations and pulmonary arterial hypertension in childhood [PDF]

, 2005
BACKGROUND: Pulmonary arterial hypertension (PAH) is a potentially fatal vasculopathy that can develop at any age. Adult-onset disease has previously been associated with mutations in BMPR2 and ALK-1.
Haworth, SG, Berger, R; id_orcid, Aldred, M A, Morrell, NW, Harrison, RE, Morrell, Nicholas W., Morrell, N W, Mache, CJ, Haworth, S G, Trembath, R C, Mache, Christoph J., Aldred, MA, Trembath, RC, Berger, Rolf, Aldred, Micheala A., Berger, R, Tulloh, R, Harrison, R E, Harrison, Rachel E., Haworth, Sheila G., Mache, C J, Trembath, Richard C., Tulloh, Robert   +22 more
core   +1 more source

A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease

ERJ Open Research, 2018
European Respiratory Society (ERS) guidelines recommend the assessment of patients with interstitial lung disease (ILD) and severe pulmonary hypertension (PH), as defined by a mean pulmonary artery pressure (mPAP) ≥35 mmHg at right heart catheterisation (
Simon Bax, Charlene Bredy, Aleksander Kempny, Konstantinos Dimopoulos, Anand Devaraj, Simon Walsh, Joseph Jacob, Arjun Nair, Maria Kokosi, Gregory Keir, Vasileios Kouranos, Peter M. George, Colm McCabe, Michael Wilde, Athol Wells, Wei Li, Stephen John Wort, Laura C. Price   +17 more
doaj   +1 more source

Tadalafil in patients with chronic obstructive pulmonary disease:a randomised, double-blind, parallel-group, placebo-controlled trial [PDF]

, 2014
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in patients with idiopathic pulmonary arterial hypertension.
Lipworth, Brian J., Hopkinson, Pippa J, Struthers, Allan D., Goudie, Andrew R, Hopkinson, Pippa J., Lipworth, Brian J, Goudie, Andrew R., Wei, Li, Struthers, Allan D   +8 more
core   +1 more source

Pathogenesis of chronic obstructive pulmonary disease [PDF]

, 2005
The current paradigm for the pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Airspace inflammation appears to be different
Macnee, W
core   +1 more source

Adult congenital heart disease: Past, present, future

International Journal of Cardiology Congenital Heart Disease, 2020
The diagnosis and management of congenital heart disease (CHD), the most common inborn defect, has been a tremendous success story of modern medicine. In the 1950s survival of children born with CHD was only approximately 15%, whereas nowadays more than ...
Margarita Brida, Michael A. Gatzoulis
doaj   +1 more source